@entity1140 or infliximab for severe XXXX : short-term and long-term data from a retrospective observational study.

@entity1 @entity5467 @entity31 @entity1140
OBJECTIVE: Treatment of severe @entity31 ( @entity31 ) is challenging. Although the efficacy of @entity1140 ( @entity5467 ) and infliximab (IFX) have been evaluated in @entity1 with severe @entity31 , the safety and efficacy levels of sequential therapies ( @entity5467 > IFX/IFX > @entity5467 ) in these @entity1 remain unclear. The aim of this study was to assess short-term and long-term outcomes in @entity1 with severe @entity31 treated with @entity5467 and IFX. METHODS: From October 2001 to February 2014, 29 @entity1 with consecutive severe @entity31 treated with @entity5467 or IFX were retrospectively evaluated. Median follow-up duration was 27   months (range 0.5-118   months). The primary end point was short-term outcomes at 8   weeks after induction of @entity5467 ( @entity5467 group, n=22) or IFX (IFX group, n=7). The secondary end point included long-term outcomes and colectomy-free survival. The clinical response was evaluated based on a partial Mayo score. RESULTS: The clinical remission (CR) rate at 8   weeks in the @entity5467 and IFX groups was 63.6% and 71.4%, respectively. In 13 of the 29 @entity1 (10 in the @entity5467 group, 3 in the IFX group), sequential therapies were used in their clinical courses. In 9 of these 13 @entity1 (6 in the @entity5467 group, 3 in the IFX group), CR was achieved and maintained by sequential therapies. Overall cumulative colectomy-free survival was 79.3% at 118   months. CONCLUSIONS: @entity5467 and IFX had similar effects on remission induction in @entity1 with severely active @entity31 . Sequential therapies could rescue @entity1 with @entity31 who failed initial treatment with @entity5467 or IFX. In clinical practice, sequential therapies might be deliberately performed.
